CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Most importantly for clinical translation, VK3 treatment of CD34+ CML cells from patients abrogated their colony-forming capacity in vitro and cleared CML blasts in a patient-derived xenograft model14.